Research Builds On Positive ECHELON-1 Study in Hodgkin Lymphoma
Tatyana Feldman, MD, director of T cell program at the John Theurer Cancer Center, Hackensack Meridian Health, discusses how research is now building upon the positive results from the phase III ECHELON-1 study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.<br />
Tatyana Feldman, MD, director of T cell program at the John Theurer Cancer Center, Hackensack Meridian Health, discusses how research is now building upon the positive results from the phase III ECHELON-1 study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
ECHELON-1 demonstrated the role of brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in patients with stage III or IV classical Hodgkin lymphoma. This regimen was previously approved by the FDA for the treatment of newly diagnosed patients with stage III/IV Hodgkin lymphoma, and new safety findings still support this indication.
To build on these positive results, Feldman says groups are designing clinical trials that incorporate novel therapies like brentuximab vedotin and PD-1 inhibitors as backbone therapy and in earlier-stagedisease.
Another larger study is evaluating the role of novel agents as treatment of patients with advanced Hodgkin lymphoma. Feldman says the field is evolving, and we will get answers in a few years when these data are available.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
